Cardio-oncology guidelines for BTKi toxicities in CLL: how are they used in clinical practice?

Описание к видео Cardio-oncology guidelines for BTKi toxicities in CLL: how are they used in clinical practice?

Inhye Ahn, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the guidelines surrounding cardiovascular toxicity associated with BTK inhibitors (BTKis), which suggest that a grade 3 event or higher should encourage clinicians to alter drug dosing. Dr Ahn also reflects on the need to better understand BTKi cardiovascular toxicities. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке

Похожие видео